Last updated: April 25, 2026
Who Supplies FEXOFENADINE HYDROCHLORIDE for “ALLERGY” Drugs?
Fexofenadine hydrochloride used in “allergy” products is typically sourced through two supply routes: (1) API (active pharmaceutical ingredient) manufacturers and (2) formulation-grade packaging chains that buy API plus excipients. Without an identified marketed product name (brand or ANDA/MAH), the only defensible answer is the supply landscape by API-grade manufacture and commercial intermediates used to build fexofenadine hydrochloride.
What does the fexofenadine supply chain look like?
- API route: API manufacturers produce fexofenadine (free base) and/or fexofenadine hydrochloride (salt form). The hydrochloride is commonly produced by salt formation from fexofenadine base using hydrochloric acid under controlled conditions.
- Formulation route: Companies buy API and formulate into tablets (most commonly). The API spec is tied to identity, assay, impurities, residual solvents, particle size, and salt form.
Which suppliers manufacture fexofenadine (API) and/or fexofenadine hydrochloride (salt)?
Fexofenadine is widely sourced from established generic API suppliers and specialty intermediates manufacturers. The supplier list below reflects the typical set of companies that produce fexofenadine API globally and/or support salt formation and commercialization.
| Supplier type |
What they supply |
Typical customer |
| API manufacturers |
Fexofenadine API (often free base) |
Generic and branded formulators |
| Salt form specialists |
Fexofenadine hydrochloride (salt) |
Formulators that require a defined salt form |
| Intermediate makers |
Key intermediates used in fexofenadine synthesis |
API manufacturers and contract synthesis partners |
Market-ready supplier set (API manufacturing and salt formation capability)
The most relevant business targets for procurement and diligence are API manufacturers that have:
- GMP manufacturing for APIs
- documented impurity profiles suitable for regulatory filings
- capability to supply consistent polymorphic and salt form specifications for fexofenadine hydrochloride
The supplier set below is the actionable shortlist used in industry for fexofenadine supply-chain coverage:
1) Cipla Ltd. (API supply presence in major generic categories; routinely involved as API/formulation supplier across allergy products)
2) Sun Pharma (API manufacturing footprint and generic API supply capability)
3) Dr. Reddy’s Laboratories (API manufacturing network; supplies to global generics)
4) Sandoz (Novartis generic platform; API and formulation supply integration)
5) Teva (API and finished dosage supply chain coverage in respiratory/allergy categories)
6) Lupin (API and intermediates network; supplies to global generics)
7) Torrent Pharmaceuticals (API manufacturing capability used for off-patent products)
8) Aurobindo Pharma (API manufacturing scale and generic supply role)
9) Hetero Labs (API manufacturing presence; supplies generic finished and API components)
10) Mylan/Viatris (generic supply chain across allergy indications)
How procurement teams verify “fexofenadine hydrochloride” availability
Procurement diligence should target evidence that the supplier’s documentation matches the salt form and regulatory requirements used in the target dossier or finished product.
Minimum verification points:
- Salt identity: “fexofenadine hydrochloride” (not only free base) in the COA and batch documentation
- GMP status: API site qualification and inspection history
- Regulatory linkage: supplier’s capability is consistent with marketed ANDA/DMF/CEP references (where applicable)
- Quality package: typical inclusion of COA, impurity report, residual solvents, and polymorph/salt form confirmation
What regulatory references typically control supplier selection?
For fexofenadine allergy products, suppliers are usually selected based on whether their API supports:
- US FDA ANDA filings (for generic products)
- EU CEP support (for salt form and impurity controls)
- DMF linkage (where referenced in filings)
These references govern impurity thresholds, salt form stability, and manufacturing controls that procurement must match to ensure defensible supply.
How do you map the supplier to actual “allergy” products?
Fexofenadine is marketed in multiple “allergy” formats and strengths, commonly including:
- Fexofenadine HCl 30 mg
- Fexofenadine HCl 60 mg
- Fexofenadine HCl 120 mg
- Fexofenadine HCl 180 mg (often once-daily)
Supplier selection should map to:
- the salt form and strength in the finished drug (tablet/coating requirements can affect allowable excipients and particle size)
- the manufacturing pathway (direct compression or granulation can constrain API particle size distribution and moisture content)
- packaging and shelf-life needs (API stability affects finished product shelf-life)
Are there common intermediate suppliers for fexofenadine hydrochloride?
Most API manufacturers source at least some synthesis inputs from intermediate producers, particularly for steps that define impurity behavior. Intermediate supply is less visible than final API supply, but the procurement control points are the same:
- impurity profile control for fexofenadine
- consistency in crystalline properties
- salt conversion reliability for hydrochloride
What supplier sourcing strategy reduces risk for fexofenadine HCl?
A practical sourcing plan for business teams is to:
- dual-source the API manufacturer (primary and secondary approved vendors)
- dual-source the salt-form process if conversion is done by a different vendor
- require batch-to-batch consistency evidence tied to impurity specs
- lock specs for water content, particle size distribution, and residual solvents at the contract stage
Key Takeaways
- Fexofenadine hydrochloride used in “allergy” drugs is sourced primarily from API manufacturers and, in some cases, salt-formation specialists.
- Supplier due diligence must confirm the exact salt form: fexofenadine hydrochloride, not only free base.
- Procurement should align supplier documentation with the regulatory control points used in ANDA/CEP/DMF-linked filings.
- The most actionable supplier targets are large-scale generic API networks with demonstrated GMP supply continuity in allergy categories.
FAQs
1) What form do suppliers typically sell: fexofenadine or fexofenadine hydrochloride?
Many sell fexofenadine base; fexofenadine hydrochloride is supplied either directly or via salt formation with documented salt-form control.
2) What is the key spec that most often blocks qualification?
Impurity profile and salt form confirmation tied to the regulatory submission expectations for the specific finished product strength.
3) How many suppliers are standard for a stable fexofenadine HCl supply?
Two approved vendors is common practice to avoid single-site disruptions.
4) Do finished-dose manufacturers always buy fexofenadine hydrochloride as a pre-made salt?
Not always. Some formulations use fexofenadine base and convert or specify salt form through the manufacturing control strategy; this must match dossier expectations.
5) Where do procurement teams verify supplier quality?
COA and batch documentation plus inspection/GMP history for the API site, mapped to the filing reference (ANDA/DMF/CEP linkage where applicable).
References
[1] U.S. Food and Drug Administration. Drug Approval Reports / Drug Databases (access route via FDA drug approval and ANDA information). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. European public assessment reports and product information for generic medicines with fexofenadine hydrochloride. https://www.ema.europa.eu/
[3] World Health Organization. WHO guidelines and quality expectations for pharmaceutical substances (general API quality framework). https://www.who.int/teams/health-product-policy-standards-and-technology/standards-and-specifications/
